Maternal administration of the acyclovir prodrug valacyclovir is compatible with pregnancy and breastfeeding. However, the safety profile of prolonged infant and maternal exposure to acyclovir in the context of antiretrovirals (ARVs) for prevention of mother-to-child HIV-1 transmission (PMTCT) has not been described.
Pregnant Kenyan women co-infected with HIV-1/HSV-2 with CD4 counts > 250 cells/mm3 were enrolled at 34 weeks gestation and randomized to twice daily 500 mg valacyclovir or placebo until 12 months postpartum. Women received zidovudine from 28 weeks gestation and single dose nevirapine was given to women and infants at the time of delivery for PMTCT. Infant blood was collected at 6 weeks for creatinine and ALT. Breast milk specimens were collected at 2 weeks postpartum from 71 women in the valacyclovir arm; acyclovir levels were determined for a random sample of 44 (62%) specimens. Fisher’s Exact and Wilcoxon rank-sum tests were used for analysis.
One hundred forty-eight women were randomized and 146 mother-infant pairs were followed postpartum. PMTCT ARVs were administered to 98% of infants and all mothers. Valacyclovir was not associated with infant or maternal toxicities or adverse events, and no congenital malformations were observed. Infant creatinine levels were all normal (< 0.83 mg/dl) and median creatinine (median 0.50 mg/dl) and infant growth did not differ between study arms. Acyclovir was detected in 35 (80%) of 44 breast milk samples collected at 2 weeks postpartum. Median and maximum acyclovir levels were 2.62 and 10.15 mg/ml, respectively (interquartile range 0.6–4.19).
Exposure to PMTCT ARVs and acyclovir after maternal administration of valacyclovir during pregnancy and postpartum to women co-infected with HIV-1/HSV-2 was not associated with an increase in infant or maternal toxicities or adverse events.
Citation: Drake AL, Roxby AC, Kiarie J, Richardson BA, Wald A, John-Stewart G, et al. (2012) Infant Safety during and after Maternal Valacyclovir Therapy in Conjunction with Antiretroviral HIV-1 Prophylaxis in a Randomized Clinical Trial. PLoS ONE 7(4): e34635. https://doi.org/10.1371/journal.pone.0034635
Editor: Ravi Jhaveri, Duke University School of Medicine, United States of America
Received: October 11, 2011; Accepted: March 2, 2012; Published: April 11, 2012
Copyright: © 2012 Drake et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (NIH) [R03 HD057773, R03 HD057773–02S1, and K24 AI087399 to CF; K24 HD054314 to G.J.S.; K24 AI071113 and PO1 AI30731 to AW; University of Washington CFAR (UW CFAR) P30 AI027757; International AIDS Research and Training Program by the Fogarty International Center (FIC) D43-TW00007; FIC R24 TW007988 to ACR; University of Washington Center for AIDS Research (UW CFAR) core P30 AI027757; UW CFAR T32 AI0714032 to ALD], University of Washington Department of Epidemiology Small Grants Program; Puget Sound Partners for Global Health Research Technology Grant to BAR, and University of Washington Royalty Research Fund Grant  to C.F. GlaxoSmithKline donated study drug (http://www.gsk.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: ALD, ACR, JK, GJS, BAR, and CF declared that no competing interests exist. AW received grant support from GlaxoSmithKline and has been a consultant for AiCuris. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Herpes simplex virus type 2 (HSV-2) is the most common cause of genital ulcer disease worldwide. Antiviral treatment for HSV-2 with acyclovir or valacyclovir during pregnancy has been shown to have important clinical benefits, such as reducing genital shedding of HSV-2 and genital ulcers during pregnancy, which are risk factors for mother-to-child HSV-2 transmission.  The prevalence of HSV-2 infection among HIV-1 infected women is high, with >75% of women co-infected in some regions. ,  Genital ulcers resulting from HSV-2 infection are more common among HIV-1 infected women,  and have been associated with a 3–5 times higher risk of mother-to-child HIV-1 transmission. ,  Maternal benefits of HSV-2 suppression include reduced frequency and severity of HSV-2 reactivations, which may also improve maternal health or reduce risk of HIV-1 transmission.
Valacyclovir is a prodrug of acyclovir, which is rapidly absorbed and converted to acyclovir and is 3–5 times more bioavailable than acyclovir. ,  Both acyclovir and valacyclovir have good safety profiles in pregnant women and infants and have not been associated with congenital malformations or infant toxicity. , ,  However, the safety profile of these drugs has not been previously described in the context of zidovudine (ZDV) and nevirapine (NVP) antiretroviral (ARV) prophylaxis for prevention of mother-to-child HIV-1 transmission (PMTCT) and data on prolonged infant exposure to acyclovir through breast milk is lacking. Acyclovir concentrations are reported to be higher in both amniotic fluid and breast milk than maternal blood, ,  and data from animal models suggest the combination of acyclovir and ZDV increases fetal exposure to both drugs.  Although previous data suggests the concentration of acyclovir in breast milk is low, equivalent to < 2% of a pediatric dose,  PMTCT ARVs may alter the pharmacokinetics of acyclovir in breast milk compartments.
We evaluated infant safety during and after prolonged maternal valacyclovir therapy administered in conjunction with antiretrovirals for PMTCT prophylaxis within a randomized clinical trial of HSV-2 suppression of twice daily 500 mg valacyclovir versus placebo in HIV-1/HSV-2 co-infected pregnant and postpartum Kenyan women. We measured the concentration of acyclovir in breast milk in order to determine the levels of acyclovir infants were exposed to through breast milk when dually exposed to acyclovir and ARV prophylaxis for PMTCT. As a secondary outcome, we also evaluated the safety of valacyclovir in HIV-1 infected pregnant and postpartum women receiving PMTCT prophylaxis.
Written informed consent was obtained from study participants and all study procedures were approved by ethical review committees at the University of Washington and the University of Nairobi.
At an antenatal clinic in Nairobi, Kenya, we enrolled 148 HIV-1/HSV-2 co-infected pregnant women at 34 weeks gestation who were not eligible for highly active ARV therapy: CD4 > 250 cells/mm3 and World Health Organization (WHO) stage 1 or 2 between April 2008 and June 2009.  The study was completed in August 2010 after the last follow-up visit was completed. At enrollment, women were randomized in a 1∶1 allocation scheme to receive twice daily 500 mg valacyclovir or matching placebo for the remainder of their pregnancy and for 12 months postpartum. Women were scheduled for follow-up study visits at 38 weeks gestation and at 2, 6, 10, and 14 weeks and 6, 9, and 12 months postpartum. At each study visit a questionnaire was administered and physical exam conducted, either by a study nurse or by one of two study physicians. Maternal blood samples were collected at enrollment and antenatal follow-up for creatinine assays. A breast milk sample was collected from all women at 2 weeks postpartum and a convenience sample of 44 breast milk specimens collected from women in the valacyclovir arm were tested for acyclovir concentrations (Advion BioSciences, Inc, Ithaca, NY). Advion BioSciences developed a method for use during this study for determining acyclovir concentrations in breast milk using liquid chromatography-mass spectrometry, with a lower limit of quantification of 0.1 ng/mL. Intra- and inter-assay accuracy ranges were −12.12% to 12.87% (mean 0.001%) and 11.51% to −4.83% (mean −7.08%), respectively. The ranges (mean) of intra- and inter-assay precision, measured as percent coefficient of variability, were 0.44% to 14.5% (4.84%) and 3.01% to 5.83% (3.71%), respectively. The sample size calculations for the clinical trial have been previously described .
Infants were brought to the clinic at all study visits for physical exams and blood was collected at 6 weeks for ALT and creatinine assays. Women were asked to return to the study clinic for interim visits if they were ill or their infant was ill, and were asked to return at monthly interim visits for pill refills after the 6 month study visit. The clinical trial was regularly reviewed by an external data safety and monitoring board and is registered at http://clinicaltrials.gov (Identification number NCT00530777).
There were no criteria for stopping the trial, other than safety. Sequentially numbered study identifiers were randomly generated by an independent, off-site researcher with block sizes of 20. Study participants were sequentially enrolled. All study investigators and participants were blinded until the end of the study.
Adverse Events and Statistical Analysis
Infants that were stillborn or second-born twins were excluded in the infant analysis. Similarly, women without at least one antenatal study visit or at least one postpartum study visit were excluded in the maternal antenatal and postpartum analyses, respectively. Cause of death and reason for hospitalizations were collected from study participants and medical records, if available. In the event of maternal death, cause of death was obtained from family or community members in addition to available medical records. The 2004 Division of AIDS Table was used to grade the severity of adverse events.  The incidence of adverse events, allowing for recurrences, was compared between study arms using the Andersen-Gill method.  The 2006 WHO reference population was used to calculate age and gender adjusted Z-scores for infant height and weight.  Linear mixed effects models were constructed to evaluate the effect of maternal treatment arm on Z-scores for infant height and weight over 12 months of follow-up. Frequencies of categorical variables were compared using Fisher’s Exact tests and distributions of continuous variables were compared using Wilcoxon rank-sum tests. Mean baseline HIV-1 RNA levels were compared between arms using t-tests. Incidence rate ratios (IRR) were calculated to compare incidence of adverse events between study arms. A Cox regression model was constructed to evaluate the effect of maternal study arm on time to infant death. Statistical analyses were conducted using Stata version 11.1 (StataCorp LP, College Station, Texas).
A total of 148 women were enrolled in the study, 74 randomized to valacyclovir and 74 randomized to placebo; 146 (99%) completed at least one study visit after delivery and are included in this analysis. The median age of participants was 25 (interquartile range [IQR], 22–29), 79% were married, and the median CD4 count was 459 cells/mm3 (IQR, 342–573 cells/mm3). All women received antenatal ZDV for PMTCT; the median gestational age at initiation was 29 weeks and median duration of antenatal ZDV use was 9.7 weeks. In addition, 140 (98%) women received PMTCT prophylaxis during labor or postpartum: 92% single dose nevirapine (sdNVP) in labor, 4 (3%) postpartum ZDV, 9 (6%) 3TC during labor or postpartum. There were no differences in baseline demographic or clinical characteristics between women randomized to the valacyclovir or placebo arms (Table 1). The CONSORT flow diagram has been previously published .
Among the 146 deliveries, 143 infants were live-born infants and 3 were stillborn (1 valacyclovir, 2 placebo). A total of 85 (59%) infants were female and median gestational age at delivery was 39.3 weeks. Risk of cesarean section was higher in the valacyclovir arm (12%) than the placebo arm (7%), but this difference was not statistically significant (p = 0.40). Nearly all (98%) infants received PMTCT prophylaxis: 137 (96%) sdNVP at birth, 143 (98%) postnatal ZDV, and 20 (14%) postnatal 3TC. Total infant follow-up time was similar between arms: 64.6 person-years in placebo and 68.2 person-years in valacyclovir. The majority of infants (97%) were breastfed with a median duration of 6.0 months in the placebo arm and 5.3 months in the valacyclovir arm (IQR 3.4–6.5 months, both arms). Comparison of plasma, cervical and breast milk HIV-1 viral levels, the primary outcomes of the randomized clinical trial have been previously described .
Infant Safety after Exposure to Acyclovir in Utero and through Breast Milk
The median duration of in utero exposure to acyclovir was 5.3 weeks (IQR 3.7 – 6.0 weeks). After in utero exposure to maternal ARV prophylaxis, and acyclovir for women in the valacyclovir arm, none of the infants were born with congenital malformations. Median birth weights were similar in infants born to women in the valacyclovir (3.2 kg, IQR 2.9–3.5) and placebo (3.0 kg, IQR 2.9–3.5) arms (p = 0.09); the proportion of infants born premature (<37 weeks gestation) was also similar (19% vs. 13%, p = 0.36).
During the first year of life, 7 infants in the placebo arm and 2 infants in the valacyclovir arm died (Hazard Ratio (HR) 0.27, 95% CI: 0.06–1.32, p = 0.11) (Table 2). Infant hospitalizations and deaths by maternal study arm are summarized in Table 2. The incidence of infant adverse events by study arm is shown in Table 3. The incidence of pneumonia was somewhat higher among infants in the valacyclovir arm than the placebo arm (0.39 vs. 0.22 per 100 person-years, p = 0.08). Infants in the valacyclovir arm were less likely to have eczema (IRR 0.29; p = 0.02) and oral thrush (IRR 0.67; p = 0.05) than infants in the placebo arm. There were no other major differences in the incidence of infant adverse events between study arms. Furthermore, infant growth over time was similar between arms; there were no significant differences in the mean change, or rate of change, in Z-scores for infant weight or height during 12 months of follow-up.
Among the 122 infants with serum collected at 6 weeks, all creatinine levels were normal and the distribution was similar in the valacyclovir and placebo arms (median [range]: 0.49 mg/dl [0.19–0.83] and 0.51 mg/dl [0.30–0.86], respectively). Median ALT levels at 6 weeks were also similar (26.7 U/L [range 12.6–52.4] in placebo, 26.5 U/L [range 10.6–70.1] in valacyclovir) and all levels were within the normal range, with the exception of 1 infant with an ALT level of 70.1 U/L (Grade 1) in the valacyclovir arm .
Among women randomized to valacyclovir, 71 had breast milk samples collected at 2 weeks postpartum and 44 of these samples were randomly chosen to test for acyclovir concentrations. Acyclovir was detected in 35 (80%) breast milk samples; the median concentration was 2.62 µg/ml (IQR 0.6–4.19) and range was 0.15 to 10.15 µg/ml. At the 2 week postpartum visit, all women self-reported the number of doses missed in the last 2 days. Women with detectable levels of acyclovir were significantly more likely to report fewer doses missed (p = 0.03, Fisher’s Exact). Among the 9 women with undetectable levels of acyclovir in breast milk samples, 1 (11%) missed all 4 doses, 2 (22%) missed 2 doses, and 6 (67%) did not miss any doses. In contrast, among the 35 women with detectable levels of acyclovir none missed all doses, 1 (3%) missed 2 doses, 4 (11%) missed 3 doses, and 30 (80%) did not miss any doses.
Maternal safety outcomes were analyzed separately for antenatal and postpartum follow-up. After excluding 43 women who delivered prior to 38 weeks gestation and 3 women without an antenatal follow-up sample, 100 women were included in the pregnancy analysis. Genital ulcers were only found in one woman in the placebo arm during pelvic exam; none were found in the valacyclovir arm. Other adverse events for women during pregnancy were minor and primarily consisted of headache, cough, vomiting, vaginal discharge, urinary tract infection, and weight loss. The only adverse event that was more frequent in women in the valacyclovir group was fever; 5 women reported fevers in the valacyclovir arm for an incidence of 1.02 per 100 person-years and no fevers were reported in the placebo arm (p = 0.03) (Table 4). Median serum creatinine at enrollment was the same in both arms (0.74 mg/dL) and all antenatal follow-up levels fell within the normal range; median creatinine change from enrollment to 38 weeks gestation was 0.03 mg/dL in the placebo arm and 0.05 mg/dL in the valacyclovir arm. There were no hospitalizations or maternal deaths during pregnancy; the only severe adverse events that occurred during pregnancy were 3 women with stillbirths (above).
There were 73 women in each study arm included in the postpartum analysis; 1 woman in each arm was lost to follow-up prior to delivery. The median duration of postpartum follow-up was 12 months in both arms and the total follow-up time was 69.3 person-years in the valacyclovir arm and 69.8 person-years in the placebo arm. Overall retention was high with 136 (93%) of women completing the 12 month postpartum visit; median adherence to study drug by pill count was 86% in both arms (IQR 80% to 92%). Three women were hospitalized during postpartum follow-up for the following reasons: severe depression (valacyclovir); gastroenteritis (valacyclovir); and malaria and severe anemia (placebo). Three women also died during postpartum follow-up. One woman in the valacyclovir arm died with peripheral edema and chest pain, which was not considered to be related to the study drug. Two women died in the placebo arm; one died of a hemorrhage at 3 weeks postpartum and may have had undiagnosed tuberculosis, and the other died with abdominal pain with vomiting and diarrhea. The most frequently reported maternal postpartum adverse events included cough, upper respiratory infections, headache, backache, chest pain, and abdominal pain; there were no differences in the incidence of these events between study arms (Table 5). The risk of dizziness (IRR = 0.50, p = 0.03) and yeast infections (IRR 0.36, p = 0.04) were higher in the placebo than valacyclovir arm; incidence of all other reported adverse events was similar between study arms.
We did not detect any association between valacyclovir and congenital malformations, infant adverse events, or infant toxicities after exposure in utero and through breast milk following administration of maternal valacyclovir and PMTCT ARVs during pregnancy and postpartum. The absence of infant kidney and liver toxicity suggests that valacyclovir exposure does not increase the risk of nevirapine-associated liver toxicity. We also observed that acyclovir was detected in breast milk at low levels at 2 weeks postpartum, demonstrating a low level of infant exposure to acyclovir through breast milk. The median concentration of 2.62 µg/mL was similar to the average breast milk concentration reported in a pharmacokinetic study by Sheffield et al conducted in U.S. women who were not HIV-1 infected.  Assuming infants ingest 750 mL/day of breast milk, the cumulative exposure to acyclovir for infants in this study over the course of 1 year would be 717 mg (2.62 µg/mL × 750 mL/day × 365 days). For comparison, this is 79% lower than the cumulative exposure from intravenous treatment of neonatal herpes administered over only 14–21 days .
The incidences of adverse events for pregnant and postpartum women were also similar between study arms, with the exception of fever during pregnancy which was more frequent among women in the valacyclovir arm. However, 3 of 5 fevers were reported only at interim visits and were not measured. Fever has not previously been reported as a side effect of valacyclovir, and is unlikely to be related to valacyclovir suppressive therapy.
Our infant and maternal safety results are consistent with prior studies of HSV-2 antiviral use during pregnancy and breastfeeding. , , ,  However, safety data on prolonged exposure to acyclovir in utero and in breast milk from these studies are limited. Concerns about in utero acyclovir exposure stem from pharmacokinetic data that have shown an accumulation of acyclovir in amniotic fluid at levels higher than maternal plasma; however, acyclovir has not been found to accumulate in the fetus. ,  The absence of any clinically significant adverse events in dually exposed infants suggests the safety profile is similar to infants exposed to acyclovir or ZDV alone; however, we did not evaluate pharmacokinetics of acyclovir in infants and could not ascertain whether PMTCT ARV prophylaxis with ZDV potentiates infant exposure to acyclovir, as has been suggested in one animal study .
Our study is unique in that it used a combination of laboratory assays and clinical indicators to ascertain infant and maternal safety both during pregnancy and for 1 year postpartum, captured serial infant growth measurements, and evaluated safety exposure to valacyclovir in combination with PMTCT ARVs. However, our study was subject to some limitations. We were unable to determine infant acyclovir concentrations, lacked knowledge regarding the timing between dosing and breast milk sample collection, and did not evaluate infant neutropenia, which has been observed in some neonates with herpes treated with high dose intravenous acyclovir.  In addition, we cannot determine whether acyclovir was not detected in breast milk for some women in the valacyclovir arm due to over-reporting adherence, the inability of our assay to detect low concentrations of acyclovir, or because breast milk sample collection occurred too long after the last dose was administered. Although we did not detect any difference in congenital malformations between study arms, valacyclovir suppressive therapy was started late in pregnancy, at 34 weeks gestation, and we are unable to address risk at earlier gestations. Finally, use of block randomization could compromise allocation concealment and lead to selection bias; however we did not detect any statistical differences in maternal baseline characteristics between arms.
Acyclovir and valacyclovir are currently used in developed settings for chronic HSV-2 suppression, including pregnant women with recurrent genital herpes.  Our study provides additional safety information on tolerability and safety of acyclovir during late pregnancy, and it includes longer follow-up of than prior studies of valacyclovir in the US (12 months vs. 2 weeks).  Antiviral use in resource-limited settings may become more widespread, due to the frequency and severity of HSV-2 reactivations in HIV-1 infected persons coupled with WHO recommendations to use acyclovir for syndromic management of lesions consistent with genital herpes. In addition, HSV-2 suppressive therapy slows HIV-1 disease progression.  If antivirals for HSV do become more widely used in HIV-1/HSV-2 co-infected individuals, demonstrating infant and maternal safety of dual exposure to valacyclovir and PMTCT ARVs could help to expand the benefit of HSV-2 suppression in resource-limited settings to pregnant or breastfeeding women.
Maternally administered valacyclovir suppressive therapy used in conjunction with short-course PMTCT ARVs was well tolerated among infants and HIV-1 infected pregnant and postpartum women. Our data suggest PMTCT ARVs do not alter the safety profile of valacyclovir in these women and their perinatally exposed infants; valacyclovir suppression should be considered as a mechanism to reduce HSV-2 recurrences during late pregnancy and breastfeeding among HIV-1 infected women receiving short course ARVs for PMTCT, when clinically indicated.
We would like to thank our participants and study staff at the Mathare North City Council Clinic for their time and dedication to this study, and our data safety and monitoring committee for their review throughout the study.
Conceived and designed the experiments: ALD JK BAR AW GJS CF. Performed the experiments: ACR. Analyzed the data: ALD BAR. Contributed reagents/materials/analysis tools: AW. Wrote the paper: ALD ACR AW GJS CF.
- 1. Hollier L, Wendel G (2008) Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev. CD004946 p.
- 2. Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, et al. (2007) Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission. Obstet Gynecol 109: 403–409.
- 3. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, et al. (2000) Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 182: 1090–1096.
- 4. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, et al. (1997) Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol 177: 450–454.
- 5. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, et al. (2001) Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183: 206–212.
- 6. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, et al. (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54: 595–605.
- 7. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, et al. (2002) Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 13: 12–21.
- 8. Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304: 859–866.
- 9. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, et al. (2004) Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res A Clin Mol Teratol 70: 201–207.
- 10. Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, et al. (2011) Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 365: 1284–1292.
- 11. Jacquemard F, Yamamoto M, Costa JM, Romand S, Jaqz-Aigrain E, et al. (2007) Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG 114: 1113–1121.
- 12. Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, et al. (2002) Acyclovir concentrations in human breast milk after valaciclovir administration. Am J Obstet Gynecol 186: 100–102.
- 13. Brown SD, Bartlett MG, White CA (2003) Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats. Antimicrob Agents Chemother 47: 991–996.
- 14. Drake AL, Roxby AC, Ongecha-Owuor F, Kiarie J, Wald A, et al. (2011) Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. J Infect Dis 205: 366–375.
- 15. National Institute for Allergy and Infectious Disease (NIAID). Division of AIDS Toxicity Table for Grading the Severity of Adult and Pediatric Adverse Events, Publish Date December (2004) Available at http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS_AE_GradingTable_FinalDec2004.pdf. Accessed May 31, 2011.
- 16. Andersen PK, Gill RD (1982) Cox's Regression Model for Counting Processes: A Large Sample Study. Ann Statist 10: 1100–1120.
- 17. World Heatlh Organization. (2006) WHO Child Growth Standards.
- 18. American Academy of Pediatrics (2009) Herpes Simplex. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL. pp. 363–373.
- 19. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, et al. (1991) Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 164: 569–576.
- 20. Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, et al. (1998) Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 179: 846–851.
- 21. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, et al. (2001) Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 108: 230–238.
- 22. American College of Obstetrics and Gynecologists (ACOG) (.2007) ACOG Practice Bulletin. Management of herpes in pregnancy. Clinical management guidelines for obstetrician-gynecologists. No. 82 June (2007) Management of herpes in pregnancy. Obstet Gynecol 109: 1489–1498.
- 23. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, et al. (2006) Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol 194: 774–781.
- 24. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824–833.